Medical Economics March 31, 2025
Richard Payerchin

Key Takeaways

  • The FTC stresses the importance of 23andMe maintaining its privacy commitments during bankruptcy, ensuring user data protection.
  • FTC commissioners Slaughter and Bedoya challenge their dismissal, citing a 90-year legal precedent against unlawful removal.
  • Concerns are raised about the influence of billionaires on government actions, potentially undermining consumer protection efforts.
  • The legal battle highlights tensions between the rule of law and perceived corporate influence in government decisions.

Meanwhile, FTC members contest removal by Trump.

Personal information must be kept confidential as genetic testing company 23andMe works its way through bankruptcy court, according to the leader of the Federal Trade Commission (FTC).

Meanwhile, at least two FTC members say they were fired wrongly from their posts, and they...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Govt Agencies, Pharma / Biotech, Precision Medicine
23andMe is potentially selling more than just genetic data. Survey info is just as much a privacy problem
AIDAVA is harnessing data altruism to advance personalised medicine
The Download: generative AI therapy, and the future of 23andMe’s genetic data
23andMe: How to delete your genetic data
23andMe Bankruptcy Court Could Appoint A Privacy Ombudsman. Will It?

Share This Article